Recently, the Category 1 innovative drug, Sulbactam Sodium for Injection/Durlobactam Sodium for Injection (co-packaged) (trade name: 鼎优乐/XACDURO) of Entasis Therapeutics, Inc. is approved for marketing through the priority review and approval procedure by China NMPA. This drug is indicated for the treatment of hospital acquired bacterial pneumonia (HABP), ventilator associated bacterial pneumonia (VABP) in patients 18 years of age and older caused by susceptible isolates of Acinetobacter baumannii-calcifaciens acetate complex.

This product is a combination packaged product containing both sulbactam sodium for injection and durlobactam sodium for injection. Sulbactam is a β-lactam antimicrobial and Ambler A serine β-lactamase inhibitor while dulobactam is a diazabicyclooctane, non-β-lactam β-lactamase inhibitor that protects sulbactam from degradation by β-lactamase. The marketing of this drug provides a new treatment option for patients with HABP and VABP caused by susceptible isolates of the Acinetobacter baumannii-calcium acetate complex.